Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET OVEREXPRESSION ( ENST00000318493.11 )
MET OVEREXPRESSION ( ENST00000318493.11 )
Associated Disease
uveal melanoma
Source Database
CIViC Evidence
Description
c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiRNA mediated MET-knockdown reduced cell migration but not cell growth. Crizotinib treatment led to a decrease in cell growth and migration. At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased. Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1583
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/621
Rating
1
Evidence Type
Predictive
Disease
Uveal Melanoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
24140933
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue